WHO Drug Information, Vol. 15, No. 3-4, 2001                                                Recommended INN: List 46




International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names
(Rec. INN): List 46
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (173) and Recommended (135) International Nonproprietary Names can be found in Cumulative
List No. 9, 1996.


Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES
(DCI Rec): Liste 46
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations
communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60,
3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par lOrganisation
mondiale de la Santé en tant que dénominations communes internationales recommandées. Linclusion dune dénomination
dans les listes de DCI recommandées nimplique aucune recommandation en vue de lutilisation de la substance
correspondante en médecine ou en pharmacie.
On trouvera dautres listes de Dénominations communes internationales proposées (173) et recommandées (135)
dans la Liste récapitulative No. 9, 1996.


Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales
RECOMENDADAS
(DCI Rec.): Lista 46
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (173) y Recomendadas (135) se encuentran
reunidas en Cumulative List No. 9, 1996.


                                                                                                                       187
Recommended INN: List 46                                                   WHO Drug Information, Vol. 15, No. 3-4, 2001




Latin, English, French, Spanish:
Recommended INN         Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée       Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada       Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada



abrineurinum
abrineurin                            N-L-methionylneurotrophic factor (human brain-derived) cyclic
                                      (13→80),(58→109),(68→111)-tris(disulfide), dimer

abrineurine                           dimère du (13→80),(58→109),(68→111)-tris(disulfure) cyclique du
                                      L-méthionylfacteur neurotrophique cerébral humain


abrineurina                           dímero del (13→80),(58→109),(68→111)-tris(disulfuro)cíclico del factor
                                      N-L-metionilneurotrófico (derivado de cerebro humano)

                                      C587H947N177O177S10 (monomer)


                                                                                                            M
                                      HSDPARRGEL              SVCDSISEWV     TAADKKTAVD         MSGGTVTVLE
                                      KVPVSKGQLK              QYFYETKCNP      MGYTKEGCRG        IDKRHWNSQC
                                      RTTQSYVRAL              TMDSKKRIGW      RFIRIDTSCV        CTLTIKRGR




acidum carglumicum
carglumic acid                        N-carbamoyl-L-glutamic acid

acide carglumique                     acide (2S)-2-(carbamoylamino)pentanedioïque

ácido carglúmico                      ácido N-carbamoil-L-glutámico

                                      C6H10N2O5


                                                        NH2
                                                  O
                                                      H NH

                                      HO2C              CO2H




188
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                 Recommended INN: List 46




acidum lidadronicum
lidadronic acid                       [1-amino-3-(dimethylamino)propylidene]diphosphonic acid

acide lidadronique                    acide [1-amino-3-(diméthylamino)propylidène]bisphosphonique

ácido lidadrónico                     ácido[1-amino-3-(dimetilamino)propiliden]difosfónico

                                      C5H16N2O6P2


                                                  OH
                                                     O
                                                 P OH
                                             H2N    OH
                                       H3C
                                           N       P OH
                                               CH3       O




agalsidasum alfa
agalsidase alfa                       human alpha-galactosidase isoenzyme A, isolated from human cell line,
                                      clone RAG 001, glycoform α

agalsidase alfa                       isoenzyme A de lalpha-galactosidase humaine (dimère), glycoforme α
                                      produit par la lignée humaine RAG 001

agalsidasa alfa                       isoenzima A de la alfa-galactosidasa humana glicosilada, aislada de cultivos
                                      de células humanas RAG 001, glicoforma α

                                      C2029H3080N544O587S27
                                      (subunit protein moiety
                                      reduced)


                                      LDNGLARTPT          MGWLHWERFM            CNLDCQEEPD            SCISEKLFME
                                      MAELMVSEGW          KDAGYEYLCI            DDCWMAPQRD            SEGRLQADPQ
                                                                                       *
                                      RFPHGIRQLA          NYVHSKGLKL            GIYADVGNKT            CAGFPGSFGY
                                      YDIDAQTFAD          WGVDLLKFDG            CYCDSLENLA            DGYKHMSLAL
                                      *                                            *
                                      NRTGRSIVYS          CEWPLYMWPF            QKPNYTEIRQ            YCNHWRNFAD
                                      IDDSWKSIKS          ILDWTSFNQE            RIVDVAGPGG            WNDPDMLVIG
                                      NFGLSWNQQV          TQMALWAIMA            APLFMSNDLR            HISPQAKALL
                                      QDKDVIAINQ          DPLGKQGYQL            RQGDNFEVWE            RPLSGLAWAV
                                      AMINRQEIGG          PRSYTIAVAS            LGKGVACNPA            CFITQLLPVK
                                      RKLGFYEWTS          RLRSHINPTG            TVLLQLENTM            QMSLKDLL
                                                         * glycosylation sites (asparagine)
                                                         * sites de glycosylation (asparagine)
                                                         * posiciones de glicosilación (asparagine)




                                                                                                                   189
Recommended INN: List 46                                     WHO Drug Information, Vol. 15, No. 3-4, 2001




agalsidasum beta
agalsidase beta            α-galactosidase (human clone λAG18 isoenzyme A subunit protein moiety
                           reduced), glycoform β

agalsidase bêta            isoenzyme A de lalpha-galactosidase humaine (dimère dont la partie
                           protéique est codée par lADN de cellules λAG18 humaines) glycoforme β
                           produit par culture de cellules ovariennes de hamster chinois (CHO)

agalsidasa beta            isoenzima A de la α-galactosidasa, fracción proteíca reducida obtenida del
                           clon humano λAG18, glicoforma β

                           C2029H3080N544O587S27
                           (subunit protein moiety
                           reduced)

                           LDNGLARTPT              MGWLHWERFM    CNLDCQEEPD        SCISEKLFME
                           MAELMVSEGW              KDAGYEYLCI    DDCWMAPQRD        SEGRLQADPQ
                           RFPHGIRQLA              NYVHSKGLKL    GIYADVGNKT        CAGFPGSFGY
                           YDIDAQTFAD              WGVDLLKFDG    CYCDSLENLA        DGYKHMSLAL
                           NRTGRSIVYS              CEWPLYMWPF    QKPNYTEIRQ        YCNHWRNFAD
                           IDDSWKSIKS              ILDWTSFNQE    RIVDVAGPGG        WNDPDMLVIG
                           NFGLSWNQQV              TQMALWAIMA    APLFMSNDLR        HISPQAKALL
                           QDKDVIAINQ              DPLGKQGYQL    RQGDNFEVWE        RPLSGLAWAV
                           AMINRQEIGG              PRSYTIAVAS    LGKGVACNPA        CFITQLLPVK
                           RKLGFYEWTS              RLRSHINPTG    TVLLQLENTM        QMSLKDLL


alefaceptum
alefacept                  1-92-antigen LFA-3 (human) fusion protein with human immunoglobulin G1
                           (hinge-CH2-CH3 γ1-chain), dimer

aléfacept                  dimère de la protéine de fusion entre le 1-92-LFA-3 humain et la région
                           charnière CH2-CH3 de la chaîne γ1 de limmunoglobuline G1 humaine

alefacept                  dímero de la proteína de fusión entre el 1-92-antígeno LFA-3 humano y la
                           immunoglobulina G1 (cadena γ1 bisagra-CH2-CH3)

                           C3264H5002N840O988S20



                             FSQQIYGVVY            GNVTFHVPSN     VPLKEVLWKK         QKDKVAELEN
                             SEFRAFSSFK            NRVYLDTVSG     SLTIYNLTSS         DEDEYEMESP
                             NITDTMKFFL            YVDKTHTCPP     CPAPELLGGP         SVFLFPPKPK
                             DTLMISRTPE            VTCVVVDVSH     EDPEVKFNWY         VDGVEVHNAK
                             TKPREEQYNS            TYRVVSVLTV     LHQDWLNGKE         YKCKVSNKAL
                             PAPIEKTISK            AKGQPREPQV     YTLPPSRDEL         TKNQVSLTCL
                             VKGFYPSDIA            VEWESNGQPE     NNYKTTPPVL         DSDGSFFLYS
                             KLTVDKSRWQ            QGNVFSCSVM     HEALHNHYTQ         KSLSLSPGK
                                                                                                      2



190
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                   Recommended INN: List 46




 alfatradiolum
 alfatradiol                            estra-1,3,5(10)-triene-3,17α-diol

 alfatradiol                            estra-1,3,5(10)-triène-3,17α-diol

 alfatradiol                            estra-1,3,5(10)-trieno-3,17α-diol

                                        C18H24O2


                                                                   CH3 OH
                                                                         H
                                                               H

                                                           H       H
                                         HO




 aprepitantum
 aprepitant                             3-[[(2R,3S)-3-(p-fluorophenyl)-2-[[(αR)-α-methyl-
                                        3,5-bis(trifluoromethyl)benzyl]oxy]morpholino]methyl]-∆3-1,2,4-triazolin-5-one

 aprépitant                             5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-3-
                                        (4-fluorophényl)morpholin-4-yl]méthyl]-1,2-dihydro-3H-1,2,4-triazol-3-one

 aprepitant                             5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi]-
                                        3-(4-fluorofenil)morfolin-4-il]metil]-1,2-dihidro-3H-1,2,4-triazol-3-ona

                                        C23H21F7N4O3


                                          O
                                                   N               O       H CH3
                                         HN                            H
                                                           N                             CF3
                                               N                       O
                                               H
                                                               H

                                                                                   CF3
                                                       F




 atrasentanum
 atrasentan                             (2R,3R,4S)-1-[(dibutylcarbamoyl)methyl]-2-(p-methoxyphenyl)-
                                        4-[3,4-(methylenedioxy)phenyl]-3-pyrrolidinecarboxylic acid

 atrasentan                             acide (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoéthyl]-
                                        2-(4-méthoxyphényl)pyrrolidine-3-carboxylique

 atrasentán                             ácido (2R,3R,4S)-1-[(dibutilcarbamoil)metil]-2-(p-metoxifenil)-
                                        4-[3,4-(metilenodioxi)fenil]-3-pirrolidinacarboxílico




                                                                                                                   191
Recommended INN: List 46                                               WHO Drug Information, Vol. 15, No. 3-4, 2001




                           C29H38N2O6


                                                      CO2H         O
                                              H
                                          H                        O
                                                             H
                                                  N              CH3
                           H3 CO
                                                       N         CH3
                                              O




aviscuminum
aviscumine                 toxin ML-I (mistletoe lectin I) (Viscum album)

aviscumine                 toxine ML-I (lectine I de gui) (Viscum album) obtenue par génie génétique,
                           constituée par deux chaînes peptidiques A (250 amino-acides) et B (264
                           amino-acides) liées entre elles par un pont disulfure

aviscumina                 toxina ML-I (lectina I de muérdago) (Viscum album) obtenida por ingeniaria
                           genética, constituida por dos cadenas peptídicas A (250 aminoácidos) y B
                           (264 aminoácidos) unidas entre sí por un puente disulfuro

                           C1251H1956N346O374S5 (A)
                           C1255H1983N363O394S15 (B)



                           MYERIRLRVT                 HQTTGEEYFR          FITLLRDYVS        SGSFSNEIPL
                           LRQSTIPVSD                 AQRFVLVELT          NQGGDSITAA        IDVTNLYVVA
                           YQAGDQSYFL                 RDAPRGAETH          LFTGTTRSSL        PFNGSYPDLE
                           RYAGHRDQIP                 LGIDQLIQSV          TALRFPGGST        RTQARSILIL
                           IQMISEAARF                 NPILWRARQY          INSGASFLPD        VYMLELETSW
                           GQQSTQVQHS                 TDGVFNNPIR          LAIPPGNFVT        LTNVRDVIAS
                           LAIMLFVCGE

                           MDDVTCSASE                 PTVRIVGRNG          MCVDVRDDDF        RDGNQIQLWP
                           SKSNNDPNQL                 WTIKRDGTIR          SNGSCLTTYG        YTAGVYVMIF
                           DCNTAVREAT                 LWQIWGNGTI          INPRSNLVLA        ASSGIKGTTL
                           TVQTLDYTLG                 QGWLAGNDTA          PREVTIYGFR        DLCMESNGGS
                           VWVETCVSSQ                 KNQRWALYGD          GSIRPKQNQD        QCLTCGRDSV
                           STVINIVSCS                 AGSSGQRWVF          TNEGAILNLK        NGLAMDVAQA
                           NPKLRRIIIY                 PATGKPNQMW          LPVP




192
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                  Recommended INN: List 46




balaglitazonum
balaglitazone                         (±)-5-[p-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]benzyl]-
                                      2,4-thiazolidinedione

balaglitazone                         (5RS)-5-[4-[(3-méthyl-4-oxo-3,4-dihydroquinazolin-
                                      2-yl)méthoxy]benzyl]thiazolidine-2,4-dione

balaglitazona                         (±)-5-[p-[(3,4-dihidro-3-metil-4-oxo-2-quinazolinil)metoxi]bencil]-
                                      2,4-tiazolidinadiona

                                      C20H17N3O4S




                                                   N                       O        and enantiomer
                                                             O                      et énantiomère
                                       O       N                      S             y enantiómero
                                                                            NH
                                               CH3
                                                                      H     O




bimosiamosum
bimosiamose                           [hexane-1,6-diylbis[6-(α-D-mannopyranosyloxy)biphenyl-
                                      3',3-diyl]]diacetic acid

bimosiamose                           acide [hexane-1,6-diylbis[6-(α-D-mannopyranosyloxy)biphényle-
                                      3',3-diyl]]diacétique

bimosiamosa                           ácido [hexano-1,6-diilbis[6-(α-D-manopiranosiloxi)bifenil-
                                      3',3-diil]]diacético

                                      C46H54O16

                                                                 HO

                                                                                O               CO2H
                                                         CO2H
                                       HO                                 OH HO
                                                                 HO                 O
                                                     O

                                            OH HO
                                       HO                O




                                                                                                                  193
Recommended INN: List 46                                             WHO Drug Information, Vol. 15, No. 3-4, 2001




brostallicinum
brostallicin               4-(2-bromoacrylamido)-N-(2-guanidinoethyl)-1,1,1,1-tetramethyl-
                           N,4:N,4:N,4-quater[pyrrole-2-carboxamide]

brostallicine              4-[[[4-[[[4-[[[4-[(2-bromoprop-2-énoyl)amino]-1-méthyl-1H-pyrrol-
                           2-yl]carbonyl]amino]-1-méthyl-1H-pyrrol-2-yl]carbonyl]amino]-1-méthyl-
                           1H-pyrrol-2-yl]carbonyl]amino]-N-(2-guanidinoéthyl)-1-méthyl-1H-pyrrol-
                           2-carboxamide

brostalicina               4-(2-bromoacrilamido)-N-(2-guanidinoetil)-1,1,1,1-tetrametil-
                           N,4:N,4:N,4-cuater[pirrol-2-carboxamida]

                           C30H35BrN12O5




                                                     CH3                    CH3
                                                             O
                                                                        N
                                                     N                               O
                                                                 N
                                            O                    H
                                                                                HN               CH3
                                 H3C            NH                                          N
                                       N                                                          H
                                                                                                  N        NH
                                 Br                                                         O          N
                                                                                                       H    NH2
                                           NH
                           H2C
                                      O




dabigatranum
dabigatran                 N-[[2-[(p-amidinoanilino)methyl]-1-methyl-5-benzimidazolyl]carbonyl]-
                           N-2-pyridyl-β-alanine

dabigatran                 acide 3-[[[2-[[[4-(aminoiminométhyl)phényl]amino]méthyl]-1-méthyl-
                           1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoïque

dabigatrán                 N-[[2-[(p-amidinoanilino)metil]-1-metil-5-benzimidazolil]carbonil]-N-2-piridil-
                           β-alanina

                           C25H25N7O3




                            HN                                        O
                                                NH       N                               CO 2H
                                                                            N
                           H2N
                                                         N            N
                                                     H3 C




194
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                       Recommended INN: List 46




diflomotecanum
diflomotecan                          (5R)-5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-
                                      3H,15H-oxepino[3,4:6,7]indolizino[1,2-b]quinoline-3,15-dione

diflomotécan                          (5R)-5-éthyl-9,10-difluoro-5-hydroxy-1,4,5,13-tétrahydro-
                                      3H,15H-oxépino[3,4:6,7]indolizino[1,2-b]quinoléine-3,15-dione

diflomotecán                          (5R)-5-etil-9,10-difluoro-1,4,5,13-tetrahidro-5-hidroxi-
                                      3H,15H-oxepino[3,4:6,7]indolizino[1,2-b]quinolina-3,15-diona

                                      C21H16F2N2O4


                                                                   O
                                                                             O
                                                               N
                                                                                    O


                                                           N           HO
                                       F                                      CH3

                                           F




edotreotidum
edotreotide                           N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-
                                      D-phenylalanyl- L-cysteinyl-L-tyrosyl- D-tryptophyl-L-lysyl- L-threonyl-
                                      N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L -cysteinamide cyclic
                                      (2→7)-disulfide

édotréotide                           (2→7)-disulfure cyclique du [N-[[4,7,10-tris(carboxyméthyl)-1,4,7,10-
                                      tétraazacyclododéc-1-yl]acétyl]- D-phénylalanyl]-L-cystéinyl-L -tyrosyl-
                                      D-tryptophyl- L-lysyl- L-thréonyl-[N 1-[(1R,2R)-2-hydroxy-
                                      1-(hydroxyméthyl)propyl]-L -cystéinamide]

edotreotida                           (2→7)-disulfuro cíclico de N-[[4,7,10-tris(carboximetil)-1,4,7,10-
                                      tetraazaciclododec-1-il]acetil]-D-fenilalanil-L-cisteinil-L-tirosil-D-triptofil-L-lisil-
                                      L-treonil-N-[(1R,2R)-2-hidroxi-1-(hidroximetil)propil]-L-cisteinamida


                                      C65H92N14O18S2



                                               CO2H                                                               OH
                                                                                                                   H
                                               N                                                                       CH3
                                                       N           D-Phe    Cys   Tyr   D-Trp   Lys Thr   Cys N
                                                                                                              H   H OH
                                                               O
                                           N
                                                   N
                                       CO2H                CO2H




                                                                                                                             195
Recommended INN: List 46                                          WHO Drug Information, Vol. 15, No. 3-4, 2001




edronocainum
edronocaine                N,1-dimethyl-2-(m-propoxyphenoxy)diethylamine

édronocaïne                N-méthyl-N-[2-(3-propoxyphénoxy)éthyl]propan-2-amine

edronocaina                N,1-dimetil-2-(m-propoxifenoxi)dietilamina

                           C15H25NO2


                                                           CH3
                                               O
                                                       N      CH3
                                                       CH 3

                                          O
                           H3C




eflucimibum
eflucimibe                 (S)-2-(dodecylthio)-4-hydroxy-2,3,5-trimethyl-2-phenylacetanilide

éflucimibe                 (2S)-2-(dodécylsulfanyl)-N-(4-hydroxy-2,3,5-triméthylphényl)-
                           2-phénylacétamide

eflucimiba                 (S)-2-(dodeciltio)-4-hidroxi-2,3,5-trimetil-2-fenilacetanilida

                           C29H43NO2S


                           H3C                                      S   H          CH3
                                                                             H
                                                                             N           CH3

                                                                         O
                                                                                         OH
                                                                                   CH3



eganoprostum
eganoprost                 methyl (Z)-7-[(1R,2R,3R)-2-[(1E,3S,7R)-3,7-dihydroxy-1-octenyl]-
                           3-hydroxy-5-oxocyclopentyl]-5-heptenoate

éganoprost                 (Z)-7-[(1R,2R,3R)-2-[(1E,3S,7R)-3,7-dihydroxyoct-1-ényl]-3-hydroxy-
                           5-oxocyclopentyl]hept-5-énoate de méthyle

eganoprost                 (Z)-7-[(1R,2R,3R)-2-[(1E,3S,7R)-3,7-dihidroxioct-1-enil]-3-hidroxi-
                           5-oxociclopentil]hept-5-enoato de metilo

                           C21H34O6


                                O     H
                                                              O
                                                                  CH3
                                                           O CH3
                           HO         H
                                 H            H OH      H OH


196
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                   Recommended INN: List 46




emodepsidum
emodepside                            cyclo[(R)-lactoyl-N-methyl-L-leucyl-(R)-3-(p-morpholinophenyl)lactoyl-
                                      N-methyl-L-leucyl-(R)-lactoyl-N-methyl-L-leucyl-
                                      (R)-3-(p-morpholinophenyl)lactoyl-N-methyl-L-leucyl]

émodepside                            cyclo[(R)-2-hydroxypropanoyl-(N-méthyl-L-leucyl)-[(R)-3-[4-(morpholin-
                                      4-yl)phényl]-2-hydroxypropanoyl]-(N-méthyl-L-leucyl)-
                                      (R)-2-hydroxypropanoyl-(N-méthyl-L-leucyl)-[(R)-3-[4-(morpholin-
                                      4-yl)phényl]-2-hydroxypropanoyl]-(N-méthyl-L-leucyl)]

emodepsida                            ciclo[(R)-lactoil-N-metil-L-leucil-(R)-3-(p-morfolinofenil)lactoil-N-metil-L-leucil-
                                      (R)-lactoil-N-metil-L-leucil-(R)-3-(p-morfolinofenil)lactoil-N-metil-L-leucil]

                                      C60H90N6O14


                                                    O                                 O

                                                         N                                 N




                                          H CH3         CH3 H           CH3   H CH3       CH3 H           CH3
                                                    N               N                 N               N
                                         O          Leu O           Leu       O       Leu O           Leu
                                               O                O                 O               O




erlizumabum
erlizumab                             immunoglobulin G1, anti-(human antigen CD18) (human-mouse monoclonal
                                      F(ab)2 fragment γ1-chain), disulfide with human-mouse monoclonal light
                                      chain, dimer

erlizumab                             immunoglobuline G1, anti-(antigène CD18 humain) fragment F(ab)2
                                      (chaîne γ1 de lanticorps monoclonal de souris humanisé), dimère du
                                      disulfure avec la chaîne légère de lanticorps monoclonal de souris humanisé

erlizumab                             immunoglobulina G1, anti-(antígeno CD18 humano) fragmento F(ab)2
                                      (cadena γ1 del anticuerpo monoclonal humanizado de ratón), dímero del
                                      disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de
                                      ratón




                                                                                                                        197
Recommended INN: List 46                                            WHO Drug Information, Vol. 15, No. 3-4, 2001




ertapenemum
ertapenem                  (4R,5S,6S)-3-[[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]-3-pyrrolidinyl]thio]-
                           6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-
                           2-carboxylic acid

ertapénem                  acide (4R,5S,6S)-3-[[(3S,5S)-5-[(3-carboxyphényl)carbamoyl]pyrrolidin-
                           3-yl]sulfanyl]-6-[(1R)-1-hydroxyéthyl]-4-méthyl-7-oxo-
                           1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

ertapenem                  ácido (4R,5S,6S)-3-[[(3S,5S)-5-[(3-carboxifenil)carbamoil]pirrolidin-
                           3-il]sulfanil]-6-[(1R)-1-hidroxetil]-4-metil-7-oxo-1-azabiciclo[3.2.0]hept-
                           2-eno-2-carboxílico

                           C22H25N3O7S


                                             CO2H                      CO2H
                                    O
                           H 3C          N
                                                S           O
                           HO                 H
                                  H H    H H CH3                N
                                                       N    H   H
                                                       H




etoricoxibum
etoricoxib                 5-chloro-6-methyl-3-[p-(methylsulfonyl)phenyl]-2,3-bipyridine

étoricoxib                 5-chloro-6-méthyl-3-[4-(méthylsulfonyl)phényl]-2,3-bipyridyle

etoricoxib                 5-cloro-6-metil-3-[4-(metilsulfonil)fenil]-2,3-bipiridilo

                           C18H15ClN2O2S


                               CH 3

                                    N        O O
                                              S
                                                CH3

                           N



                               Cl




198
WHO Drug Information, Vol. 15, No. 3-4, 2001                                            Recommended INN: List 46




eufauserasum
eufauserase                           broad spectrum serine-protéase enzyme, extracted from the Antartic krill
                                      (Euphausia superba)

eufausérase                           protéase à large spectre (enzyme à sérine) extraite de krill de lAntartique
                                      (Euphausia superba)

eufauserasa                           serin-proteasa de amplio espectro extraida del camarón antártico
                                      (Euphausia superba)

                                      C1170H1764N300O387S14


                                       AVENCGPVAP             RNK

                                       IVGGMEVTPH             AYPWQVGLFI     DDMYFCGGSI         ISDEWVLTAH
                                       CMDGAGFVEV             VMGAHSIHDE     TEATQVRATS         TDFFTHENWN
                                       SFTLSNDLAL              IKMPAPIEFN    DVIQPVCLPT         YTDASDDFVG
                                       ESVTLTGWGK             PSDSAFGIAE     QLREVDVTTI         TTADCQAYYG
                                       IVTDKILCID             SEGGHGSCNG     DSGGPMNYVT         GGVTQTRGIT
                                       SFGSSTGCET             GYPDGYTRVT     SYLDWIESNT         GIAIDP




farglitazarum
farglitazar                           N-(o-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-L -tyrosine

farglitazar                           acide (2S)-2-[(2-benzoylphényl)amino]-3-[4-[2-(5-méthyl-2-phényloxazol-
                                      4-yl)éthoxy]phényl]propanoïque

farglitazar                           ácido (2S)-2-[(2-benzoilfenil)amino]-3-[4-[2-(5-metil-2-feniloxazol-
                                      4-il)etoxi]fenil]propanoico

                                      C34H30N2O5


                                                                                    O


                                                    N               O
                                                                            H HN

                                                    O         CH3               CO2H




                                                                                                                     199
Recommended INN: List 46                                                   WHO Drug Information, Vol. 15, No. 3-4, 2001




fesoterodinum
fesoterodine               2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl
                           isobutyrate

fésotérodine               2-méthylpropanoate de 2-[(1R)-3-[bis(1-méthyléthyl)amino]-1-phénylpropyl]-
                           4-(hydroxyméthyl)phényle

fesoterodina               2-metilpropanoato de 2-[(1R)-3-[bis(1-metiletil)amino]-1-fenilpropil]-
                           4-(hidroximetil)fenilo

                           C26H37NO3

                                                  CH3
                                         O
                                                       CH3
                                              O       H3C       CH3

                           HO                               N       CH 3

                                                  H             CH3




gavilimomabum
gavilimomab                immunoglobulin M, anti-(human antigen CD147) (mouse monoclonal
                           ABX-CBL µ-chain), disulfide with mouse monoclonal ABX-CBL light chain,
                           pentamer

gavilimomab                immunoglobuline M, anti-(antigène CD147 humain) (chaîne µ de lanticorps
                           monoclonal de souris ABX-CBL), pentamère du disulfure avec la chaîne
                           légère de lanticorps monoclonal de souris ABX-CBL

gavilimomab                immunoglobulina M, anti-(antígeno CD147 humano) (cadena µ del anticuerpo
                           monoclonal de ratón ABX-CBL), pentámero del disulfuro con la cadena ligera
                           del anticuerpo monoclonal de ratón ABX-CBL



gemopatrilatum
gemopatrilat               (6S)-hexahydro-6-[(αS)-α-mercaptohydrocinnamido]-2,2-dimethyl-7-oxo-
                           1H-azepine-1-acetic acid

gémopatrilate              acide [(6S)-2,2-diméthyl-7-oxo-6-[[(2S)-3-phényl-
                           2-sulfanylpropanoyl]amino]hexahydro-1H-azépin-1-yl]acétique

gemopatrilat               ácido [(6S)-2,2-dimetil-7-oxo-6-[[(2S)-3-fenil-
                           2-sulfanilpropanoil]amino]hexahidro-1H-azepin-1-il]acético

                           C19H26N2O4S


                                       H SH H   O
                                              H
                                            N                         CO2H
                                                                N
                                                                    CH3
                                          O
                                                                    CH3



200
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                    Recommended INN: List 46




imatinibum
imatinib                              α-(4-methyl-1-piperazinyl)-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]-p-tolu-
                                      p-toluidide

imatinib                              4-[(4-méthylpipérazin-1-yl)méthyl]-N-[4-méthyl-3-[[4-(pyridin-3-yl)pirimidin-
                                      2-yl]amino]phényl]benzamide

imatinib                              α-(4-metil-1-piperazinil)-3-[[4-(3-piridil)-2-pirimidinil]amino]-p-tolu-p-toluidida

                                      C29H31N7O


                                                   N
                                                                      H            H
                                               N                      N            N        N          N
                                       H3C
                                                                  O                  N
                                                                                   CH3




insulinum glulisinum
insulin glulisine                     [3B-L-lysine,29B-L-glutamic acid]insulin (human)

insuline glulisine                    [3B-L-lysine,29B-L-acide glutamique]insuline humaine

insulina glulisina                    [3B-L-lisina,29B-L-ácido glutámico]insulina humana

                                      C258H384N64O78S6



                                        H Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
                                                                                       10
                                          Glu Asn Tyr Cys Asn OH
                                                         20

                                        H Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
                                                                                       10
                                             Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr OH
                                                          20                                                 30




lemalesomabum
lemalesomab                           immunoglobulin G1, anti-(human NCA-90 granulocyte cell antigen) (mouse
                                      monoclonal IMMU-MN3 γ1-chain), disulfide with mouse monoclonal
                                      IMMU-MN3 κ-chain, dimer

lémalésomab                           immunoglobuline G1, anti-(antigène cellulaire du granulocyte humain NCA-90)
                                      (chaîne γ1 de lanticorps monoclonal de souris IMMU-MN3), dimère du
                                      disulfure avec la chaîne κ de lanticorps monoclonal de souris IMMU-MN3

lemalesomab                           immunoglobulina G1, anti-(antígeno celular del granulocito humano NCA-90)
                                      (cadena γ1 del anticuerpo monoclonal de ratón IMMU-MN3), dímero del
                                      disulfuro con la cadena κ del anticuerpo monoclonal de ratón MMU-MN3




                                                                                                                         201
Recommended INN: List 46                                       WHO Drug Information, Vol. 15, No. 3-4, 2001




litomeglovirum
litomeglovir               2-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonamido]phenyl]carbamoyl]-
                           2-methylpropyl glycinate

litoméglovir               aminoacétate de 3-[[4-[[[5-(diméthylamino)naphtalén-
                           1-yl]sulfonyl]amino]phényl]amino]-2,2-diméthyl-3-oxopropyle

litomeglovir               aminoacetato de 3-[[4-[[[5-(dimetilamino)naftalen-
                           1-il]sulfonil]amino]fenil]amino]-2,2-dimetil-3-oxopropilo

                           C25H30N4O5S


                                                                                  CH3
                                                               H
                                                               N                  N
                                   O              O                S                   CH3
                           H2N                                   O O
                                       O              N
                                           H3C   CH3 H




micafunginum
micafungin                 (4R,5R)-4,5-dihydroxy-N 2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-
                           L-ornithyl-L -threonyl-trans-4-hydroxy- L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-
                           3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy- L -glutaminyl-(3S,4S)-
                           3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide

micafungine                hydrogénosulfate de 5-[(1S,2S)-2-[(2R,6S,9S,11R,12R,14aS,15S,16S,20S,
                           23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-
                           tétrahydroxy-6-[(1R)-1-hydroxyéthyl]-16-méthyl-5,8,14,19,22,25-hexaoxo-
                           9-[[4-[5-[4-(pentyloxy)phényl]isoxazol-3-yl]benzoyl]amino]-tétracosahydro-
                           1H-dipyrrolo[2,1-c:2,1-l][1,4,7,10,13,16]hexaazacyclohénicosén-23-yl]-
                           1,2-dihydroxyéthyl]-2-hydroxyphényle

micafungina                hidrógenosulfato de 5-[(1S,2S)-2-[(2R,6S,9S,11R,12R,14aS,15S,16S,20S,
                           23S,25aS)-20-[(1R)-3-amino-1-hidroxi-3-oxopropil]-2,11,12,15-tetrahidroxi-
                           6-[(1R)-1-hidroxietil]-16-metil-5,8,14,19,22,25-hexaoxo-9-[[4-[5-[4-
                           (pentiloxi)fenil]isoxazol-3-il]benzoil]amino]-tetracosahidro-1H-dipirrolo[2,1-
                           c:2,1-l][1,4,7,10,13,16]hexaazaciclohenicosen-23-il]-1,2-dihidroxietil]-
                           2-hidroxifenilo




202
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                  Recommended INN: List 46




                                      C56H71N9O23S


                                                                                                       OH
                                                                                                            H
                                                                                         HO                               O
                                                                             O     H OH H                                      SO3H
                                                                                          H            H
                                                                                        N
                                                                      H 2N                             NH                 OH
                                                                                    H                    H
                                                                             H                O
                                                                                    N     O       O
                                                                      H3C               H O                               OH
                                                                                                  O        N
                                                                             H                                        H
                                                                                                            H
                                                                             HO H                               CH3
                                                                                        NH    HN
                                                                               HO
                                                                                                        H OH
                                                                                                       O
                                                                                    H OH
                                                                                         H        NH
                                                                             N
                                                                      O

                                                                                              O
                                       H3C
                                                            O




mozenavirum
mozenavir                             (4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzylhexahydro-
                                      5,6-dihydroxy-2H-1,3-diazepin-2-one

mozénavir                             (4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-
                                      5,6-dihydroxyhexahydro-2H-1,3-diazépin-2-one

mozenavir                             (4R,5S,6S,7R)-1,3-bis(3-aminobencil)-4,7-dibencil-5,6-dihidroxihexahidro-
                                      2H-1,3-diazepin-2-ona

                                      C33H36N4O3


                                                        O                    NH2

                                               H N              N H


                                                   H             H
                                       H2N
                                                   HO           OH




                                                                                                                                      203
Recommended INN: List 46                                                 WHO Drug Information, Vol. 15, No. 3-4, 2001




navuridinum
navuridine                 3-azido-2,3-dideoxyuridine

navuridine                 1-(3-azido-2,3-didésoxy-β- D-érythro-pentofuranosyl)pyrimidine-
                           2,4(1H,3H)-dione

navuridina                 3-azido-2,3-didesoxiuridina

                           C9H11N5O4

                                                O

                                          HN

                           HO          O        N
                                          O




                                     N3



neramexanum
neramexane                 1,3,3,5,5-pentamethylcyclohexylamine

néramexane                 1,3,3,5,5-pentaméthylcyclohexanamine

neramexano                 1,3,3,5,5-pentametilciclohexilamina

                           C11H23N


                            H3C                NH2
                           H3C                  CH3



                                 H3C      CH3



nolomirolum
nolomirole                 (±)-5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthylene diisobutyrate

nolomirole                 bis(2-méthylpropanoate) de (6RS)-6-(méthylamino)-
                           5,6,7,8-tétrahydronaphtalène-1,2-diyle

nolomirol                  diisobutirato de (±)-5,6,7,8-tetrahidro-6-(metilamino)-1,2-naftileno

                           C19H27NO4


                                                          HN       CH3
                                     O                         H
                           H3C                                            and enantiomer
                                           O                              et énantiomère
                                 CH3       O        O                     y enantiómero


                                       H3C          CH3



204
WHO Drug Information, Vol. 15, No. 3-4, 2001                                           Recommended INN: List 46




omaciclovirum
omaciclovir                           9-[(R)-4-hydroxy-2-(hydroxymethyl)butyl]guanine

omaciclovir                           2-amino-9-[(2R)-4-hydroxy-2-(hydroxyméthyl)butyl]-1,9-dihydro-
                                      6H-purin-6-one

omaciclovir                           9-[(R)-4-hidroxi-2-(hidroximetil)butil]guanina

                                      C10H15N5O3


                                                  O

                                                      N
                                             HN
                                                                 OH
                                       H2N        N   N
                                                                OH
                                                          H




omalizumabum
omalizumab                            immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse
                                      monoclonal E25 clone pSVIE26 γ-chain), disulfide with human-mouse
                                      monoclonal E25 clone pSVIE26 κ-chain, dimer

omalizumab                            immunoglobuline G, anti-(région Fc de limmunoglobuline E humaine)
                                      (chaîne γ de lanticorps monoclonal de souris E25 clone pSVIE26 humanisé),
                                      dimère du disulfure avec la chaîne κ de lanticorps monoclonal de souris E25
                                      clone pSVIE26 humanisé

omalizumab                            immunoglobulina G, anti-(región Fc de la immunoglobulina E humana)
                                      (cadena γ del anticuerpo monoclonal humanizado de ratón E25 clon
                                      pSVIE26), dímero del disulfuro con la cadena κ del anticuerpo monoclonal
                                      humanizado de ratón E25 clon pSVIE26




peginterferonum alfa-2a
peginterferon alfa-2a                 mono(N2,N6-dicarboxy-L-lysyl)interferon alfa-2a, diesters with polyethylene
                                      glycol monomethyl ether
                                      The molecular mass of the pegylated part may be indicated in the name
                                      by adding a number, for example: peginterferon alfa-2a (40KD).

peginterféron alfa-2a                 interféron alfa-2a dont une des lysines en position 31, 121, 131 ou 134 est
                                      acylée par le N2,N6-bis[méthylpoly(oxyéthylène)oxycarbonyl]-L-lysyl
                                      La masse molaire de la partie polyéthyléneglycol peut être indiquée dans la
                                      DCI, par exemple: peginterféron alfa-2a (40KD).

peginterferón alfa-2a                 diésteres del mono (N2, N6 -dicarboxi- L-lisil) interferón α-2a, con
                                      polietilenglicolmonometil éter
                                      La masa molecular de la parte pegilada, si es necesario, puede indicarse en
                                      el nombre añadiendo un número, por ejemplo: peginterferón alfa-2a (40KD).




                                                                                                                 205
Recommended INN: List 46                                                  WHO Drug Information, Vol. 15, No. 3-4, 2001




                                                                                                   *
                           CDLPQTHSLG                SRRTLMLLAQ               MRKISLFSCL          KDRHDFGFPQ
                           EEFGNQFQKA                ETIPVLHEMI               QQIFNLFSTK          DSSAAWDETL
                           LDKFYTELYQ                QLNDLEACVI               QGVGVTETPL          MKEDSILAVR
                            *                        *       *
                           KYFQRITLYL                KEKKYSPCAW               EVVRAEIMRS          FSLSTNLQES
                           LRSKE
                                                 O                                        * pegylation sites
                                                                                          * sites de pégylation
                                  O
                           H 3C              O       N                                    * posiciones de pegilación
                                             n       H
                                                           O
                                                                      H
                                         O                                Interferon alfa-2a
                                  H 3C               O           N
                                                     n           H
                                                                      O




peginterferonum alfa-2b
peginterferon alfa-2b      monocarboxyinterferon alfa-2b, diesters with polyethylene glycol
                           monomethyl ether
                           The molecular mass of the pegylated part may be indicated in the name
                           by adding a number, for example: peginterferon alfa-2b (12KD).

peginterféron alfa-2b      interféron alfa 2b dont un azote de la cystéine 1 ou dune lysine 31, 121 ou
                           134 est engagé dans une liaison carbamate avec léther monométhylique
                           du polyéthylène glycol
                           La masse molaire de la partie polyéthyléneglycol peut être indiquée dans
                           la DCI, par exemple: peginterféron alfa-2b (12KD).

peginterferón alfa-2b      diésteres del monocarboxiinterferón alfa-2b con éter monometílico de
                           polietilenglicol
                           La masa molecular de la parte pegilada, si es necesario, puede indicarse en
                           el nombre añadiendo un número, por ejemplo: peginterferón alfa-2b (12KD).




                           *                                                                      *
                           CDLPQTHSLG                SRRTLMLLAQ               MRRISLFSCL          KDRHDFGFPQ
                           EEFGNQFQKA                ETIPVLHEMI               QQIFNLFSTK          DSSAAWDETL
                           LDKFYTELYQ                QLNDLEACVI               QGVGVTETPL          MKEDSILAVR
                           *                            *
                           KYFQRITLYL                KEKKYSPCAW               EVVRAEIMRS          FSLSTNLQES
                           LRSKE
                                                 O                                        * pegylation sites
                                  O                                                       * sites de pégylation
                           H3C               O           Interferon alfa-2b               * posiciones de pegilación
                                             n




206
WHO Drug Information, Vol. 15, No. 3-4, 2001                                              Recommended INN: List 46




pipendoxifenum
pipendoxifene                         2-(p-hydroxyphenyl)-3-methyl-1-[p-(2-piperidinoethoxy)benzyl]indol-5-ol

pipendoxifène                         2-(4-hydroxyphényl)-3-méthyl-1-[4-[2-(pipéridin-1-yl)éthoxy]benzyl]-
                                      1H-indol-5-ol

pipendoxifeno                         2-(4-hidroxifenil)-3-metil-1-[4-[2-(piperidin-1-il)etoxi]bencil]-1H-indol-5-ol

                                      C29H32N2O3



                                                                  O
                                                                           N



                                                      N
                                                                      OH
                                       HO
                                                       CH3




pitrakinraum
pitrakinra                            L-methionyl-[121-aspartic   acid,124-aspartic acid]interleukin-4

pitrakinra                            L-méthionyl-[121-acide   aspartique,124-acide aspartique]interleukine-4

pitrakinra                            L-metionil-[121-ácido   aspártico,124-ácido aspártico]interleucina-4

                                      C651H1054N190O200S8




                                                                                                                M
                                        HKCDITLQEI           IKTLNSLTEQ        KTLCTELTVT         DIFAASKNTT
                                        EKETFCRAAT           VLRQFYSHHE        KDTRCLGATA        QQFHRHKQLI
                                        RFLKRLDRNL           WGLAGLNSCP        VKEANQSTLE        NFLERLKTIM
                                        DEKDSKCSS




                                                                                                                       207
Recommended INN: List 46                                                     WHO Drug Information, Vol. 15, No. 3-4, 2001




pradofloxacinum
pradofloxacin              8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-octahydro-6H-
                           pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

pradofloxacine             acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-octahydro-6H-
                           pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

pradofloxacina             ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-octahidro-6H-
                           pirrolo[3,4-b]piridin-6-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico

                           C21H21FN4O3

                                    H
                                                    CN
                           HN
                                        N                     N
                                H

                                        F                             CO2H
                                                              O


reglitazarum
reglitazar                 (4RS)-4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-
                           3,5-isoxazolidinedione

réglitazar                 (4RS)-4-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]benzyl]isoxazolidine-
                           3,5-dione

reglitazar                 (4RS)-4-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]bencil]isoxazolidina-3,5-diona

                           C22H20N2O5


                                                                  O          O       O
                                            N                                               and enantiomer
                                                                                         NH et énantiomère
                                            O        CH3                                    y enantiómero
                                                                                 H       O



rivoglitazonum
rivoglitazone              (±)-5-[p-[(6-methoxy-1-methyl-2-benzimidazolyl)methoxy]benzyl]-
                           2,4-thiazolidinedione

rivoglitazone              (5RS)-5-[4-[(6-méthoxy-1-méthyl-1H-benzimidazol-2-yl)méthoxy]=
                           benzyl]thiazolidine-2,4-dione

rivoglitazona              (5RS)-5-[4-[(6-metoxi-1-metil-1H-bencimidazol-2-il)metoxi]bencil]tiazolidina-
                           2,4-diona

                           C20H19N3O4S

                           H3CO

                                                    CH3
                                                N                                O        and enantiomer
                                                          O                               et énantiomère
                                         N                                   S            y enantiómero
                                                                                  NH

                                                                             H   O

208
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                   Recommended INN: List 46




sabiporidum
sabiporide                            N-carbamimidoyl-4-[4-(1H-pyrrol-2-ylcarbonyl)piperazin-1-yl]-
                                      3-(trifluoromethyl)benzamide

sabiporide                            N-carbamimidoyl-4-[4-(1H-pyrrol-2-ylcarbonyl)pipérazin-1-yl]-
                                      3-(trifluorométhyl)benzamide

sabiporida                            N-carbamimidoil-4-[4-(1H-pirrol-2-ilcarbonil)piperazin-1-il]-
                                      3-(trifluorometil)benzamida

                                      C18H19F3N6O2

                                                                            O       NH
                                                              F3C
                                                                                N        NH2
                                                                                H
                                             NH                N
                                                      N

                                                  O


safinamidum
safinamide                            (+)-(S)-2-[[p-[(m-fluorobenzyl)oxy]benzyl]amino]propionamide

safinamide                            (2S)-2-[[4-(3-fluorobenzyloxy)benzyl]amino]propanamide

safinamida                            (+)-(S)-2-[[p-[(m-fluorobencil)oxi]bencil]amino]propionamida

                                      C17H19FN2O2

                                                                        H CH3
                                                                                    NH2
                                                                        N
                                                                        H
                                                                                O
                                                      O



                                         F


sibenadetum
sibenadet                             4-hydroxy-7-[2-[[2-[[3-(2-
                                      phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl]benzothiazol-2(3H)-one

sibénadet                             4-hydroxy-7-[2-[[2-[[3-(2-
                                      phényléthoxy)propyl]sulfonyl]éthyl]amino]éthyl]benzothiazol-2(3H)-one

sibenadet                             4-hidroxi-7-[2-[[2-[[3-(2-feniletoxi)propil]sulfonil]etil]amino]etil]benzotiazol-
                                      2(3H)-ona

                                      C22H28N2O5S2


                                                                    H
                                                                    N
                                                                         S                O
                                                                        O O
                                       HO                 S
                                               HN
                                                          O

                                                                                                                          209
Recommended INN: List 46                                                    WHO Drug Information, Vol. 15, No. 3-4, 2001




soblidotinum
soblidotin                 N2-(N,N-dimethyl-L-valyl)-N 1-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-
                           1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-
                           1-[(1S)-1-methylpropyl]-4-oxobutyl]-N1-methyl-L-valinamide

soblidotine                (2S)-2-[[(2S)-2-(diméthylamino)-3-méthylbutanoyl]amino]-N-[(1S,2R)-
                           2-méthoxy-4-[(2S)-2-[(1R,2R)-1-méthoxy-2-méthyl-3-oxo-
                           3-[(2-phényléthyl)amino]propyl]pyrrolidin-1-yl]-1-[(1S)-1-méthylpropyl]-
                           4-oxobutyl]-N,3-diméthylbutanamide

soblidotina                (2S)-2-[[(2S)-2-(dimetilamino)-3-metilbutanoil]amino]-N-[(1S,2R)-2-metoxi-
                           4-[(2S)-2-[(1R,2R)-1-metoxi-2-metil-3-oxo-3-[(2-feniletil)amino]propil]=
                           pirrolidin-1-il]-1-[(1S)-1-metilpropil]-4-oxobutil]-N,3-dimetilbutanamida

                           C39H67N5O6


                                                                                            CH3
                                           H3C         CH3     CH3
                                                                                        O    H    O
                                 CH3       O             CH 3 O H           O       H
                                             H
                                 N                         N                                       N
                           H3C               N                                  N
                                 H           H                        H                      H CH3 H
                                                       O   H
                                                                      CH3
                                H3C        CH3
                                                                    CH3


soneclosanum
soneclosan                 5-chloro-2-(p-chlorophenoxy)phenol

sonéclosan                 5-chloro-2-(4-chlorophénoxy)phénol

soneclosán                 5-cloro-2-(p-clorofenoxi)fenol

                           C12H8Cl2O2


                                      OH
                                            O


                           Cl                                  Cl

sumanirolum
sumanirole                 (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one

sumanirole                 (5R)-5-(méthylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoléin-2(1H)-one

sumanirol                  (5R)-5-(metilamino)-5,6-dihidro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ona

                           C11H13N3O


                                       O
                                HN
                                       N

                                                 H
                                           HN        CH3



210
WHO Drug Information, Vol. 15, No. 3-4, 2001                                          Recommended INN: List 46




taplitumomabum paptoxum
taplitumomab paptox                   immunoglobulin G1, anti-(human antigen CD19) (mouse monoclonal B43
                                      γ1-chain), disulfide with mouse monoclonal B43 κ-chain, dimer, disulfide
                                      with protein PAP (pokeweed antiviral)

taplitumomab paptox                   immunoglobuline G1, anti-(antigène humain CD19) (chaîne γ1 de lanticorps
                                      monoclonal de souris B43), dimère du disulfure avec la chaîne κ de
                                      lanticorps monoclonal de souris B43, disulfure avec la protéine antivirale
                                      extraite du phytolaque (PAP)

taplitumomab paptox                   immunoglobulina G1, anti-(antígeno humano CD 19) (cadena γ1 del
                                      anticuerpo monoclonal de ratón B43), dímero del disulfuro con la cadena κ
                                      del anticuerpo monoclonal de ratón B43, disulfuro con la proteína PAP
                                      (proteína antiviral de Phytolacca americana)




tezacitabinum
tezacitabine                          2-deoxy-2-[(E)-fluoromethylene]cytidine

tézacitabine                          4-amino-1-[(2E)-2-(fluorométylène)-2-désoxy-β-D-érythro-
                                      pentofuranosyl)pyrimidin-2(1H)-one

tezacitabina                          2-desoxi-2-[(E)-fluorometileno]citidina

                                      C10H12FN3O4


                                                        NH2

                                                    N

                                       HO       O       N
                                                O




                                               OH
                                                    F




                                                                                                                  211
Recommended INN: List 46                                      WHO Drug Information, Vol. 15, No. 3-4, 2001




tidembersatum
tidembersat                N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-4-chromanyl]-
                           3,5-difluorobenzamide

tidembersat                N-[(3R,4S)-6-acétyl-3-hydroxy-2,2-diméthyl-3,4-dihydro-2H-
                           1-benzopyran-4-yl]-3,5-difluorobenzamide

tidembersat                N-[(3R,4S)-6-acetil-3-hidroxi-2,2-dimetil-3,4-dihidro-2H-1-benzopiran-4-il]-
                           3,5-difluorobenzamida

                           C20H19F2NO4


                           F             F




                               O    NH         O
                               HO        H
                               H                   CH3
                           H3 C
                                    O
                            H3 C




tilmacoxibum
tilmacoxib                 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide

tilmacoxib                 4-(4-cyclohexyl-2-méthyloxazol-5-yl)-2-fluorobenzènesulfonamide

tilmacoxib                 4-(4-ciclohexil-2-metil-5-oxazolil)-2-fluorobencenosulfonamida

                           C16H19FN2O3S


                                             O O
                                              S
                                                NH2

                                               F
                               N
                                    O
                           H3C




212
WHO Drug Information, Vol. 15, No. 3-4, 2001                                              Recommended INN: List 46




tipifarnibum
tipifarnib                            (+)-6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-
                                      4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone

tipifarnib                            (+)-6-[(R)-amino(4-chlorophényl)(1-méthyl-1H-imidazol-5-yl)méthyl]-
                                      4-(3-chlorophényl)-1-méthylquinoléin-2(1H)-one

tipifarnib                            (+)-6-[(R)-amino(4-clorofenil)(1-metil-1H-imidazol-5-il)metil]-4-(3-clorofenil)-
                                      1-metilquinolina-2(1H)-ona

                                      C27H22Cl2N4O


                                                                   CH3
                                       Cl                          N        O



                                                           NH2
                                                  N       N CH
                                                               3

                                                                            Cl




tomeglovirum
tomeglovir                            N-[4-[[[5-(dimethylamino)-1-naphthyl]sulfonyl]amino]phenyl]-3-hydroxy-
                                      2,2-dimethylpropionamide

toméglovir                            N-[4-[[[5-(diméthylamino)naphtalén-1-yl]sulfonyl]amino]phényl]-3-hydroxy-
                                      2,2-diméthylpropanamide

tomeglovir                            N-[4-[[[5-(dimetilamino)naftalen-1-il]sulfonil]amino]fenil]-3-hidroxi-
                                      2,2-dimetilpropanamida

                                      C23H27N3O4S


                                                                                   CH3
                                                                   H
                                                                   N               N
                                                      O                 S              CH3
                                                                       O O
                                       HO                 N
                                            H3C       CH3 H




                                                                                                                    213
Recommended INN: List 46                                                      WHO Drug Information, Vol. 15, No. 3-4, 2001




traxoprodilum
traxoprodil                1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-phenylpiperidin-
                           4-ol

traxoprodil                1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphényl)-1-méthyléthyl]-4-phénylpipéridin-
                           4-ol

traxoprodil                1-[(1S,2S)-2-hidroxi-2-(4-hidroxifenil)-1-metiletil]-4-fenilpiperidin-4-ol

                           C20H25NO3


                                       HO
                                                         H OH
                                                     N

                                                 H3C     H
                                                                              OH



tridolgosirum
tridolgosir                (1S,2R,8R,8aR)-octahydro-1,2,8-indolizinetriol

tridolgosir                (1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol

tridolgosir                (1S,2R,8R,8aR)-octahidroindolizina-1,2,8-triol

                           C8H15NO3



                               OH       OH
                           H        H        H
                                                 OH
                                    N            H




valomaciclovirum
valomaciclovir             L-valine,    4-ester with 9-[(R)-4-hydroxy-2-(hydroxymethyl)butyl]guanine

valomaciclovir             (2S)-2-amino-3-méthylbutanoate de (3R)-3-[(2-amino-6-oxo-1,6-dihydro-
                           9H-purin-9-yl)méthyl]-4-hydroxybutyle

valomaciclovir             éster de L-valina con (3R)-3-[(2-amino-1,6-dihidro-6-oxo-9H-purin-9-il)metil]-
                           4-hidroxibutilo

                           C15H24N6O4


                                        O

                                                 N                        O
                                  HN
                                                                  O                CH3
                           H 2N         N        N
                                                                      H
                                                                          NH2 CH3
                                                         H
                                                             OH



214
WHO Drug Information, Vol. 15, No. 3-4, 2001                                                    Recommended INN: List 46




vatalanibum
vatalanib                             1-(p-chloroanilino)-4-(4-pyridylmethyl)phthalazine

vatalanib                             N-(4-chlorophényl)-4-(pyridin-4-ylméthyl)phtalazin-1-amine

vatalanib                             1-(p-cloroanilino)-4-(4-piridilmetil)ftalazina

                                      C20H15ClN4



                                                           H
                                                           N

                                                       N
                                                   N                   Cl




                                         N




visilizumabum
visilizumab                           immunoglobulin G2, anti-(human antigen CD3) (human-mouse monoclonal
                                      HuM291 γ2-chain), disulfide with human-mouse monoclonal HuM291
                                      κ-chain, dimer

visilizumab                           immunoglobuline G2, anti-(antigène CD3 humain) (chaîne γ2 de lanticorps
                                      monoclonal de souris HuM291 humanisé), dimère du disulfure avec la
                                      chaîne κ de lanticorps monoclonal de souris HuM291 humanisé

visilizumab                           immunoglobulina G2, anti-(antígeno CD3 humano) (cadena γ2 del anticuerpo
                                      monoclonal humanizado de ratón HuM291), dímero del disulfuro con la
                                      cadena κ del anticuerpo monoclonal humanizado de ratón HuM291




ximelagatranum
ximelagatran                          ethyl N-[(R)-cyclohexyl[[(2S)-2-[[4-(hydroxycarbamimidoyl)=
                                      benzyl]carbamoyl]-1-azetidinyl]carbonyl]methyl]glycinate

ximélagatran                          [[(1R)-2-[(2S)-2-[[4-[amino(hydroxyimino)méthyl]benzyl]=
                                      carbamoyl]azétidin-1-yl]-1-cyclohexyl-2-oxoéthyl]amino]acétate déthyle

ximelagatrán                          [[(1R)-2-[(2S)-2-[[4-[amino(hidroxiimino)metil]bencil]carbamoil]azetidin-1-il]-
                                      1-ciclohexil-2-oxoetil]amino]acetato de etilo

                                      C24H35N5O5


                                       HO
                                               N

                                       H2N                                      H
                                                               H
                                                               N            N               O     CH3
                                                                                    N
                                                                       H            H
                                                                   O            O       O



                                                                                                                    215
Recommended INN: List 46                                       WHO Drug Information, Vol. 15, No. 3-4, 2001




zelandopamum
zelandopam                 (-)-(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol

zélandopam                 (-)-(4S)-4-(3,4-dihydroxyphényl)-1,2,3,4-tétrahydroisoquinoléine-7,8-diol

zelandopam                 (-)-(S)-4-(3,4-dihidroxifenil)-1,2,3,4-tetrahydro-7,8-isoquinolinediol

                           C15H15NO4


                                         OH
                                               OH




                                               NH
                                         H
                           HO
                                   OH




ziralimumabum
ziralimumab                immunoglobulin M, anti-(human antigen CD147) (human monoclonal
                           ABX-RB2 µ-chain), disulfide with human monoclonal ABX-RB2 light chain,
                           pentamer

ziralimumab                immunoglobuline M, anti-(antigène CD147 humain) (chaîne µ de lanticorps
                           monoclonal humain ABX-RB2), pentamère du disulfure avec la chaîne
                           légère de lanticorps monoclonal humain ABX-RB2

ziralimumab                immunoglobulina M, anti-(antígeno CD147 humano) (cadena µ del anticuerpo
                           monoclonal humano ABX-RB2), pentámero del disulfuro con la cadena ligera
                           del anticuerpo monoclonal humano ABX-RB2




216
WHO Drug Information, Vol. 15, No. 3-4, 2001                                              Recommended INN: List 46




                    AMENDMENTS TO PREVIOUS LISTS
           MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
               MODIFICACIONES A LAS LISTAS ANTERIORES

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

p. 184 adrogolidum
       adrogolida                     sustitúyase la descripción por la siguiente:
                                      diacetato de (5aR,11bS)-4,5,5a,6,7,11b-hexahidro-
                                      2-propilbenzo[f]tieno[2,3-c]quinolina-9,10-diilo

p. 198 motexafinum
       motexafina                     sustitúyase la descripción por la siguiente:
                                      9,10-dietil-20,21-bis[2-[2-(2-metoxietoxi)etoxi]etoxi]-4,15-dimetil-8,11-imino-
                                      3,6:16,13-dinitrilo-1,18-benzodiazacicloicosina-5,14-diildipropanol

p. 205 tanomastatum
       tanomastat                     sustitúyase la descripción por la siguiente:
                                      ácido (2S)-4-(4-clorobifenil-4-il)-4-oxo-2-[(fenilsulfanil)metil]butanoico

p. 205 tebipenemum
       tebipenem                      sustitúyase la descripción por la siguiente:
                                      2-pivalato y (4R,5S,6S)-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-3-[[1-(2-tiazolin-
                                      2-il)- 3-azetidinil]sulfanil]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxilato de
                                      metileno




Recommended International Nonproprietary Names (Rec. INN): List 45
Dénominations communes internationales recommendées (DCI Rec.): Liste 45
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45
(WHO Drug Information, Vol. 15, No. 1, 2001)

p. 43   lerdelimumabum
        lerdelimumab                  replace the description by the following:
                                      immunoglobulin G4, anti-(human transforming growth factor ß2) (human
                                      monoclonal CAT-152 ã 4-chain), disulfide with human monoclonal CAT-152
                                      ë-chain, dimer

        lérdelimumab                  remplacer la description par la suivante:
                                      immunoglobuline G4, anti-(facteur de croissance transformant humain ß2)
                                      (chaine ã 4 de lanticorps monoclonal humain CAT-152), dimère du disulfure
                                      avec la chaîne ë de lanticorps monoclonal humain CAT-152

        lerdelimumab                  sustituyase la descripción por la siguiente:
                                      inmunoglobulina G4, anti-(factor ß2 de crecimiento transformador humano)
                                      (cadena ã 4 del anticuerpo monoclonal humano CAT-152), dímero del
                                      disulfuro con la cadena ë del anticuerpo monoclonal humano CAT-152




                                                                                                                        217
Recommended INN: List 46                                                  WHO Drug Information, Vol. 15, No. 3-4, 2001




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in uneven numbers of proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour
les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internatio-
nales applicables aux substances pharmaceutiques seront publiés seulement dans les numéros impaires des listes
des DCIs proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las
sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes
internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.



218
